Innovotech Inc - Asset Resilience Ratio
Innovotech Inc (IOT) has an Asset Resilience Ratio of 0.00% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Innovotech Inc for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2024)
This chart shows how Innovotech Inc's Asset Resilience Ratio has changed over time. See shareholders equity of Innovotech Inc for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Innovotech Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Innovotech Inc market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 0% |
| Short-term Investments | CA$0.00 | 0% |
| Total Liquid Assets | CA$0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Innovotech Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Innovotech Inc Industry Peers by Asset Resilience Ratio
Compare Innovotech Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sagimet Biosciences Inc. Series A Common Stock
NASDAQ:SGMT |
Biotechnology | 63.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 43.36% |
|
Inner Mongolia Furui Med Sci
SHE:300049 |
Biotechnology | 2.34% |
|
Bio-Thera Solutions Ltd
SHG:688177 |
Biotechnology | 4.09% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Gubra A/S
CO:GUBRA |
Biotechnology | 79.61% |
Annual Asset Resilience Ratio for Innovotech Inc (2021–2024)
The table below shows the annual Asset Resilience Ratio data for Innovotech Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | CA$0.00 ≈ $0.00 |
CA$3.22 Million ≈ $2.33 Million |
-- |
| 2023-12-31 | 5.60% | CA$68.14K ≈ $49.29K |
CA$1.22 Million ≈ $880.02K |
-1.08pp |
| 2022-12-31 | 6.68% | CA$81.64K ≈ $59.06K |
CA$1.22 Million ≈ $884.56K |
+1.64pp |
| 2021-12-31 | 5.04% | CA$72.20K ≈ $52.23K |
CA$1.43 Million ≈ $1.04 Million |
-- |
About Innovotech Inc
Innovotech Inc. provides assay kits used in growing microbial biofilms for research purposes in Canada, the United States, and internationally. The company offers InnovoSIL, a silver periodate antimicrobial compounds for medical applications; and MBEC Assay kit, a screening assay used to determine the efficacy of antimicrobials against biofilms of a variety of microorganisms; pre-coated MBEC Assa… Read more